top of page

Life Saving Medicines
Remove the Cause, Remove the Effect
We are a biopharmaceutical company pioneering novel therapies for life-threatening and debilitating conditions caused by an excess of harmful substances in the body
Highlighted News from Clear Scientific
Clear Scientific Attends 2026 American College of Emergency Physicians (ACEP) Scientific Assembly
Chicago, IL | Oct 2026 Co-founders, Shekar Shetty, Peter Howe, and Winston Henderson attended the 2026 American College of Emergency Physicians (ACEP) Scientific Assembly in Chicago from October 5–8. The conference convenes emergency medicine professionals nationwide for practice-changing education, hands-on training, research, innovation, and collaboration. The 2026 program highlights advances in emergency diagnosis and treatment, resuscitation and critical care, artificial
9 minutes ago
Clear Scientific Reports Positive Phase 2 Results for CS-1103, the First Investigational Therapeutic That Removes Fentanyl from the Body
Cambridge, MA | Oct 2026 PRNewswire/-- Clear Scientific, Inc. announced positive top-line results from its Phase 2 trial of CS-1103, a small-molecule sequestrant that immediately binds and inactivates fentanyl, subsequently accelerating its removal from the body into urine. The results provide validation of CS-1103's novel mechanism of action. The trial met all endpoints, with CS-1103 accelerating the removal of fentanyl in human subjects and showing a favorable safety profi
Oct 2
NIH Highlights Pioneering Research by Drs. Cotten and Marota on using CS-1103 to Reverse Meth Poisoning by Protecting Against Overheating; Low Oxygen Levels; Organ Injury; and Muscle Breakdown
Cambridge, MA | August 2026 A novel drug sequestrant-based therapeutic candidate reverses methamphetamine-induced hyperthermia and hypermetabolism and abates multiorgan toxicity in rats - ScienceDirect In a preclinical study funded by the National Institute on Drug Abuse, CS-1103 protected against methamphetamine overdose, for which there are currently no medications. This pioneering work was conducted by Dr. Joe Cotten, MD, PhD and Dr. Elie Adam, PhD at Mass General Brigham
Sep 1
bottom of page
